TITLE:
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

CONDITION:
Chronic Lymphocytic Leukemia

INTERVENTION:
Talabostat mesylate (PT-100) tablets

SUMMARY:

      The objective of this study is to assess the efficacy and safety of talabostat and rituximab
      in patients with advanced CLL who failed to respond, or have progressed following a prior
      response, to a fludarabine regimen.
    

DETAILED DESCRIPTION:

      Completion date provided represents the completion date of the grant per OOPD records
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        INCLUSION CRITERIA:

          -  Men or women 18 years of age

          -  Histopathologically confirmed diagnosis of B-CLL expressing surface CD20 of any
             detectable intensity

          -  Rai Stage III or IV. Rai Stages I and II with massive or progressive lymphadenopathy
             or hepatosplenomegaly.

          -  Primary resistance to a fludarabine regimen (no PR or CR) or progressive disease
             within 1 year of a prior response

          -  ECOG performance status 0, 1, or 2

          -  Written informed consent

        EXCLUSION CRITERIA:

          -  Therapy for CLL within 4 weeks of Study Day 1 (including chemotherapy, radiation,
             immunotherapy, cytokine or biologic [with the exception of hematopoietic growth
             factors]). Patients must have recovered from the adverse effects of prior therapy.

          -  Known primary or secondary malignancy of the central nervous system

          -  Any malignancy within the 5 years immediately prior to the first dose of study
             medication with the exception of basal cell or non-metastatic squamous cell carcinoma
             of the skin, and carcinoma in-situ of the cervix

          -  Serum creatinine >2.0mg/dL (>176 micromol/L)

          -  AST or ALT 3 x the upper limit of normal (ULN)

          -  Total bilirubin 1.5 x ULN (unless secondary to Gilbert's)

          -  Positive serology for hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody)

          -  Known positivity for HIV

          -  Prior organ allograft

          -  Concurrent comorbid medical conditions that, in the opinion of the investigator,
             preclude the safe delivery of the experimental treatment

          -  Pregnant or nursing women
      
